Revenio Group Corporation: Interim Report January 1 - March

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Revenio Group Corporation: Interim Report January 1 - March 31, 2016: Sales grew in all key market areas. Operating profit fell slightly from the previous year.

Revenio Group Corporation, Stock Exchange Release, April 25, 2016 at 9:00 am

Revenio Group Corporation Interim Report January 1 - March 31, 2016

Due to an amendment to the Securities Market Act, which came into force on November 26, 2015, the descriptive sections of Revenio's interim reports Q1/2016 and Q1-Q3/2016 will be shorter and more concise than before. The table sections will be reported in accordance with previous practices. The figures are unaudited.

Revenio Group Corporation has adopted the publication procedure enabled by the Financial Supervisory Authority's Regulations and guidelines 7/2013 (Disclosure obligation on issuers) and is publishing its financial statements bulletin for January-March 2016 as an appendix to this stock exchange release. This release is a summary of Revenio Group Corporation's Interim Report Q1/2016, which is available in full in the pdf file attached to this stock exchange release, and on the company website at www.revenio.fi .

Sales grew in all key market areas. Operating profit fell slightly from the previous year.

January-March 2016 in brief, continuing Group operations:

  • Net sales growth continued. Profitability fell slightly short of the previous year's figure, mainly due to growth investments implemented according to plan.
  • Net sales totaled EUR 5.2 million (EUR 4.6 million), showing an increase of 12.9 per cent.
  • The operating result decreased by 6.2 per cent to EUR 1.3 million (EUR 1.4 million).
  • The decrease in operating profit was due to planned human resource investments required for the global sales launch of Icare HOME and Icare ic100 tonometers, and for the asthma and skin cancer product development projects.
  • The number of personnel during the review period was 41 (29), an increase of 12 persons.
  • Earnings per share from continuing operations came to EUR 0.12 (0.16). Besides exchange rates, deferred taxes contributed to the fall in earnings per share.
  • In March Revenio reported that FDA did not grant sales permit for Icare HOME tonometer in the US. The company has started actions to submit a new sales license application.
  • After the review period in April 20, 2016 the company received notification that the FDA has granted sales permit for Icare ic100 tonometer in the US.

Key figures, continuing operations, EUR million:

  1.1.-31.3.2016 1.1-31.3.2015 Change-%
Net sales, Group 5.2 4.6 12.9
Operating profit, Group 1.3 1.4 -6.2
Net sales, Health Tech 5.2 4.6 12.9
Operating profit, Health Tech 1.6 1.7 -5.8
Undiluted earnings per share 0.12 0.16 -23.0
Diluted earnings per share 0.12 0.15 -22.7
Cash flow from operating activities 0.5 3.1 -84.8
  31  March 2016 31  March 2015 Change, %-point
Equity ratio-% 74.1 69.7 4.4
Gearing-% -24.9 -38.5 13.6

Financial guidance for 2016

Net sales growth is expected to remain strong. Profitability is expected to remain at a healthy level despite growth investments.

Business trends in Q1/2016, continuing operations

Revenio Group's net sales grew in all key market areas, amounting to EUR 5.2 million (EUR 4.6 million) and showing an increase of 12.9 per cent. Net sales were affected by the growth of sales in all key market areas, especially in the US.

Sales of the new generation Icare ic100 tonometer were successfully launched in Europe, which affected sales of the previous version, Icare TA01, to some extent.

A sales license application was filed for the Icare ic100 tonometer in the United States in December 2015. After the review period in April 20, 2016 the company received notification that the FDA has granted sales permit for Icare ic100 tonometer in the US. The company has readiness to launch Icare ic100 tonometer immediately and to deliver first lot of equipment for sale in the US markets.

Probe sales showed strong growth, up 23 per cent on the previous year, representing 28 per cent of net sales.

In March, the United States Food and Drug Administration FDA decided to reject the sales license application for Icare HOME. Icare has taken steps to initiate a new feasibility study; once this has been completed, the company will file a new sales license application with the FDA. The new application license is expected to be filed during 2016.

Revenio Research Oy's development projects on product concepts related to skin cancer and asthma are progressing as planned. Test measurements with the prototype of a device designed for skin cancer diagnostics will begin this spring.

Revenio Group's operating profit for the period amounted to EUR 1.3 million (EUR 1.4 million), falling 6.2 per cent short of the same period a year earlier. This can be primarily attributed to higher salary costs resulting from preparations for the global sales launch of Icare HOME and Icare ic100 tonometers and research and development related to asthma and skin cancer products. Recruitment focused on sales and marketing and product development personnel. Most of the recruited employees joined the company in late 2015, which has an impact on the salary costs for the period.

Olli-Pekka Salovaara, President and CEO, comments on the first quarter of 2016:

"Sales in the United States, our largest individual market area, developed as planned. Sales grew in all key market areas and organic growth continued.

An updated version of the Icare TA01i tonometer, the ic100, was granted a CE marking in Europe in late 2015 and thereby a sales permit in the EU. The market launch and sales of this new generation product in Europe began during the review period. The Icare ic100 has required significant investments, and while we expect it to gradually replace the Icare TA01i tonometer launched in 2003, we believe that the TA01 will continue to generate healthy sales for several years, particularly in developing countries. After the review period in April 20, 2016 we received notification that the FDA has granted sales permit for Icare ic100 tonometer in the US. Icare's marketing team is ready to launch this new generation product in the US market. This is a significant milestone for us.

Probe sales showed steady growth, but we expect sales to become more substantial following growth in device sales and increasingly active use of the devices.

We were very disappointed with the decision of the United States Food and Drug Administration in March to reject the sales license application for the Icare HOME tonometer, against our expectations and discussions with the authorities. After an analysis, we decided to take immediate action and to start making preparations for a new feasibility study. After this study has been completed, Icare will submit a new sales license application to the FDA, probably before the year-end.

The product concept development work carried out at Revenio Research on the detection, patient-led screening and follow up of asthma and skin cancer is proceeding as planned. Development work on the asthma detection product is progressing as planned and according to schedule. I believe we will be able to disclose more details this year on the global launch schedule for both products.

Oscare Medical has signed its first significant sales agreement with a Nordic pharmacy chain.

When assessing the development of operating profit in the second and third quarter of 2016, it is important to note that most of the twelve new employees recruited to support the global sales launches of the Icare HOME and Icare ic100, and the asthma and skin care product development projects, joined the company in the final quarter of 2015. Personnel required in support of our planned growth has now been recruited and salary costs are expected to remain at the current level throughout 2016."

General statement

Certain statements in this report are estimates based on the management's best knowledge at the time they were made. They therefore involve a certain amount of inherent risk and uncertainty. The estimates may change in the event of significant changes in general economic conditions.

Revenio Group Corporation Board of Directors

For further information, please contact: President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520 olli-pekka.salovaara@revenio.fi www.revenio.fi

DISTRIBUTION: Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4 %. Revenio Group Corporation is listed on Nasdaq Helsinki.

HUG#2006254

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 375

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Forecast Reveals Growth Surge in Healthcare IT by $199 Billion

Updated Category News Views 121

Growth Forecast for Healthcare IT Market The healthcare IT market is poised for substantial growth, projected to rise by USD 199.8 billion from 2024 to 2028. This growth is primarily fueled by an increasing emphasis on service quality and operational efficiency, alongside advancements in artificial intelligence (AI) technologies that are transforming healthcare practices....

Continue Reading
Revolutionizing Painting: Rust-Oleum's Low Odor Spray Paint

Updated Category News Views 197

Transform Your Painting Experience with Rust-Oleum For many, the smell of traditional spray paint can be quite off-putting, often making the creative process less enjoyable. Thankfully, Rust-Oleum has taken a bold step towards addressing this issue by introducing a product that fundamentally shifts the painting experience. Introducing Low Odor Premium Spray Paint...

Continue Reading
Banking Academy and Vantage Foundation Unite for Financial Growth

Updated Category News Views 116

Strategic Partnership Between Banking Academy and Vantage Foundation In an exciting development for financial education, the Banking Academy of Vietnam (BAV) and Vantage Foundation have formed a significant strategic partnership. This collaboration was marked by the signing of a Memorandum of Understanding (MoU) at the Banking Academy's headquarters, symbolizing a...

Continue Reading
Investor Alert: Dave Inc. Faces Class Action Investigation

Updated Category News Views 296

Understanding the Current Situation of Dave Inc. Recently, there has been a growing concern among shareholders of Dave Inc. (NASDAQ: DAVE) regarding potential misleading information disseminated by the company. This has prompted Rosen Law Firm, a respected advocate for investor rights, to initiate an investigation aimed at uncovering possible securities claims. As this...

Continue Reading
Exploring the Rise of GE Aerospace: Investors' Perspective

Updated Category News Views 289

Understanding GE Aerospace's Growth GE Aerospace has shown remarkable performance over recent years, outpacing the overall market significantly. For the last five years, it has delivered an astounding 38.48% return on an annualized basis, reflecting an impressive average annual return of 52.35%. This optimistic trend has contributed to its current market capitalization,...

Continue Reading